Form 4 for RGEN REPLIGEN CORP
Accepted 2025-11-26 00:00:00 ET · period of report 2025-11-25 · accession 0001193125-25-300642 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-11-26 | 2025-11-25 | RGEN | Loeillot Olivier | CEO, Dir | S - Sale | $170.00 | -7,041 | 35.9K | -16% | -$1.20M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-25 | S | D | 7,041 | $170.00 | 35,898 | D | — | — | (F1) Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on December 12, 2024. |